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Background
Systemic sclerosis (scleroderma) is a life-threatening autoimmune disease that is 
characterized by the presence of specific autoantibodies and fibrosis of the skin and 
major internal organs.
Methods
We genotyped a polymorphism (G−945C) in the promoter of the connective-tissue 
growth factor (CTGF) gene in 1000 subjects in two groups: group 1, consisting of 
200 patients with systemic sclerosis and 188 control subjects; and group 2, consisting 
of 300 patients with systemic sclerosis and 312 control subjects. The combined groups 
represented an estimated 10% of patients with systemic sclerosis in the United 
Kingdom. We tested the effect of the polymorphism on the transcription of CTGF.
Results
The GG genotype was significantly more common in patients with systemic sclerosis 
than in control subjects in both groups, with an odds ratio for the combined group 
of 2.2 (95% confidence interval [CI], 1.5 to 3.2; P<0.001 for trend). Analysis of the 
combined group of patients with systemic sclerosis showed a significant association 
between homozygosity for the G allele and the presence of anti–topoisomerase I 
antibodies (odds ratio, 3.3; 95% CI, 2.0 to 5.6; P<0.001) and fibrosing alveolitis 
(odds ratio, 3.1; 95% CI, 1.9 to 5.0; P<0.001). We observed that the substitution of 
cytosine for guanine created a binding site of the transcriptional regulators Sp1 and 
Sp3. The C allele has high affinity for Sp3 and is associated with severely reduced 
transcriptional activity. A chromatin immunoprecipitation assay showed a marked 
shift in the ratio of Sp1 to Sp3 binding at this region, demonstrating functional rel-
evance in vivo.
Conclusions
The G−945C substitution represses CTGF transcription, and the −945G allele is sig-
nificantly associated with susceptibility to systemic sclerosis.
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Systemic sclerosis (scleroderma) is a clinically heterogeneous disorder of the con-nective tissue characterized by immune ac-
tivation, vascular damage, and fibrosis.1 Major or-
gan-based complications involving the lungs, heart, 
kidneys, and gastrointestinal tract determine mor-
tality and morbidity. Moreover, the presence of 
highly specific and mutually exclusive autoantibod-
ies is associated with distinct clinical phenotypes.2
Clinical and experimental data suggest that 
the pathogenesis of systemic sclerosis is multifac-
torial, involving both genetic and environmental 
factors.3 Genetic susceptibility to systemic sclero-
sis is complex, involving several genes and chro-
mosomal loci4 with small and probably additive 
individual effects.
The expression of the gene encoding connec-
tive-tissue growth factor (CTGF), also known as 
CCN2, has been found to be greatly up-regulated 
in gene-expression–profiling studies of skin-biopsy 
specimens5,6 and of fibroblasts cultured from 
skin7 and lung tissue (unpublished data) from pa-
tients with systemic sclerosis. Moreover, CTGF 
has been associated with key biologic functions, 
including fibroblast proliferation, the production 
of extracellular matrix, and the formation of ad-
hesion and granulation tissue,8 processes that are 
relevant to systemic sclerosis. Indirect genetic 
evidence of the involvement of the CTGF gene in 
the pathogenesis of systemic sclerosis is provid-
ed in a recent study of monozygotic and dizy-
gotic twins that showed a concordant increase 
in the expression of CTGF in monozygotic twins 
who were discordant for systemic sclerosis.9 In 
addition, genomewide screening of specimens ob-
tained from Choctaw Indians of North America, 
who have a high incidence of systemic sclerosis, 
identified one region in particular, 6q23–27, to 
which a large number of genes, including CTGF, 
map.10 Taking all of these observations into ac-
count, we hypothesized that variations in the 
promoter region of CTGF confer susceptibility to 
systemic sclerosis.
Me thods
Study Patients
We enrolled 500 white patients (426 women and 
74 men) with systemic sclerosis, who fulfilled the 
preliminary criteria of the American College of 
Rheumatology for the disease,11 and 500 healthy 
white unrelated control subjects. Of these partici-
pants, 200 patients with systemic sclerosis and 
188 control subjects were included in the initial 
screening group (group 1), and 300 patients with 
systemic sclerosis and 312 control subjects were 
assessed in the second group (group 2) (Table 1). 
All patients with systemic sclerosis were under-
going treatment at the Royal Free Hospital or the 
Royal Brompton Hospital in London or the Royal 
National Hospital for Rheumatic Diseases in Bath, 
and complete clinical and serologic information 
was available. The control samples were collected 
from healthy volunteers from the above-mentioned 
three hospitals and were unrelated to the patients 
with systemic sclerosis. Data on race and ethnic 
background were recorded from the patients’ med-
ical records. For the control subjects, this informa-
tion was self-reported as part of an open-ended 
questionnaire completed during the enrollment 
interview.
Systemic sclerosis was classified as either a 
limited subtype or a diffuse subtype according 
to the extent of the skin involved, as proposed by 
LeRoy et al.12 The presence of fibrosing alveolitis, 
scleroderma renal crisis, and isolated pulmonary 
Table 1. Clinical and Serologic Characteristics of Patients with Systemic Sclerosis.
Variable
Total
(N = 500)
Group 1
(N = 200)
Group 2
(N = 300)
number (percent)
Sex
Female 426 (85.2) 166 (83.0) 260 (86.7)
Male 74 (14.8) 34 (17.0) 40 (13.3)
Skin involvement
Limited 364 (72.8) 137 (68.5) 227 (75.7)
Diffuse 136 (27.2) 63 (31.5) 73 (24.3)
Organ involvement
Fibrosing alveolitis 207 (41.4) 87 (43.5) 120 (40.0)
Isolated pulmonary  
arterial hypertension
44 (8.8) 22 (11.0) 22 (7.3)
Scleroderma renal crisis 52 (10.4) 36 (18.0) 16 (5.3)
No internal-organ  
involvement*
224 (44.8) 72 (36.0) 152 (50.7)
Antibodies
Anti–topoisomerase I 155 (31.0) 54 (27.0) 101 (33.7)
Anticentromere 166 (33.2) 58 (29.0) 108 (36.0)
No anti–topoisomerase I 
or anticentromere
179 (35.8) 88 (44.0) 91 (30.3)
* Patients in this category did not have fibrosing alveolitis, isolated pulmonary 
arterial hypertension, or scleroderma renal crisis.
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arterial hypertension was defined according to 
internationally accepted criteria (see Methods in 
the Supplementary Appendix, available with the 
full text of this article at www.nejm.org). These 
clinically defined groups were not exclusive and 
consisted of 207 patients with fibrosing alveolitis, 
44 with isolated pulmonary arterial hypertension, 
and 52 with scleroderma renal crisis (24 patients 
had fibrosing alveolitis with scleroderma renal 
crisis and 3 had isolated pulmonary arterial hyper-
tension with scleroderma renal crisis); 224 pa-
tients had none of these complications. (The latter 
group was defined as having systemic sclerosis 
with no internal-organ involvement.)
Patients with systemic sclerosis were also clas-
sified into three nonoverlapping autoantibody 
subgroups: 155 patients had anti–topoisomerase 
I antibodies, 166 had anticentromere antibodies, 
and 179 patients had neither of these antibodies. 
(More detailed information about the group with-
out either anti–topoisomerase I or anticentromere 
antibodies is provided in Table 1 of the Supple-
mentary Appendix.) Autoantibody specificities 
were determined by standard methods that have 
been described previously.13,14 The frequency and 
type of organ involvement in both groups are 
shown in Table 1.
Written informed consent was obtained from 
all subjects, and the study was approved by the 
ethics committee at the Royal Free Hospital.
Identification of Sequence Variants
We compared sequences of the CTGF promoter 
region available in the National Center for Biotech-
nology Information’s GenBank database (www.
ncbi.nlm.nih.gov/entrez/query.fcgi?db=nucleotide) 
and directly sequenced approximately 1 kb of se-
quence upstream from the transcription start site15 
from 10 subjects.
The sequences across polymorphic sites (30 bp) 
were analyzed for putative nuclear-factor–binding 
sites by a search of transcription-factor–binding 
sites (TFBIND at http://tfbind.ims.u-tokyo.ac.jp).16 
Several single-nucleotide polymorphisms (SNPs) 
of low frequency were detected and are now all 
deposited in GenBank’s dbSNP database. A com-
mon SNP, which was described previously as 
located at position −743 bp from the transcrip-
tion start site,17 has since been included in the 
dbSNP database at position −945 from the ATG 
start codon (rs6918698). Because of this SNP’s 
high frequency and location in a putative tran-
scriptional element, we further investigated it in 
our study, and we adhere to the official reference 
of its location at −945 in this article.
Genotyping
Genotyping was performed with the use of a 
polymerase-chain-reaction (PCR) assay with se-
quence-specific primers,18 as detailed in the Sup-
plementary Appendix. The genotypes of 25 ran-
dom samples were confirmed by direct sequencing 
by MGW Biotech.
Cell Culture
We isolated lung fibroblasts as described previ-
ously.19 The cells were cultured under standard 
conditions in Dulbecco’s modified Eagle’s medi-
um containing 10% fetal-calf serum. For transient 
transfection experiments, the cells were placed 
in 0.2% fetal-calf serum for 10 hours and then 
treated with fresh 0.2% fetal-calf serum with or 
without 1 U of thrombin per milliliter for 16 hours. 
For the electrophoretic mobility-shift assay (EMSA) 
and chromatin immunoprecipitation assay, cells 
were harvested after 24 hours in 0.2% fetal-calf 
serum. For all experiments except the chromatin 
immunoprecipitation assay, we used the same 
preparation of cells, at passage 4 to 7, from one 
patient with systemic sclerosis. For the chroma-
tin immunoprecipitation assay, cell preparations 
from 13 subjects were genotyped and four homo-
zygotes were selected: two control lines, genotypes 
CC and GG; and two systemic sclerosis lines, gen-
otypes CC and GG.
Plasmid Constructs and Promoter-Activity 
Assays
To generate the parent CTGF promoter–reporter 
construct, we cloned a 4.6-kb fragment of the 
CTGF gene from a P1-derived artificial chromo-
some clone (provided by Andrew Mungal, Sanger 
Institute, Cambridge, United Kingdom; GenBank 
accession number, AL354866) into the luciferase 
(Luc) reporter vector pGL3 (Promega) (see the Sup-
plementary Appendix). This construct, which con-
tains 4.5 kb of CTGF promoter sequence, was de-
noted as p-4.5–CTGF–Luc. We amplified a 1.6-kb 
fragment spanning the polymorphism from nine 
unrelated subjects who had previously been geno-
typed as homozygotes. After restriction enzyme 
digestion, which generates PmeI- and SacII-com-
patible sites at the ends, the resulting 1.5-kb frag-
ments were cloned into the parent construct p-4.5–
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CTGF–Luc. The 10 constructs were transiently 
transfected into human lung fibroblasts overnight 
with the use of Fugene 6 (Roche). After treatment, 
cells were lysed with the use of Reporter Gene 
Assay Lysis Buffer (Roche), and luciferase was 
measured with the use of luciferase reagents (Pro-
mega) in a chemiluminometer (Mithras LB 940, 
Berthold Technologies). A thymidine kinase pro-
moter–renilla luciferase reporter plasmid (pRL-TK, 
Promega) was used as a transfection efficiency 
control. Triplicate wells were tested, and experi-
ments were repeated at least twice. The parent con-
struct, p-4.5–CTGF–Luc, was subjected to site-direct-
ed mutagenesis with the use of the QuikChange 
II XL kit (Stratagene) to make the substitution of 
guanine for cytosine at position −945. Primers 
used were forward ATTGATGGCCACTCCTCCC-
TTGTCCTTGCC and reverse GGCAAGGACAAG-
GGAGGAGTGGCCATCAAT. The two constructs 
were used in transient cotransfection assays, to-
gether with pCMV-Sp3 (provided by Guntram 
Suske),20 or the empty vector control pCMV, as 
described above.
DNA-Binding Assays
For EMSA, we prepared nuclear extracts from hu-
man lung fibroblasts as described previously21 
and used these extracts in binding reactions with 
32P-labeled double-stranded oligonucleotides span-
ning the polymorphic site: top-strand C allele oli-
gonucleotide CATTGATGGCCACTCCTCCCTTG-
TCCTTGCC and top-strand G allele oligonucleotide 
CATTGATGGCCACTCGTCCCTTGTCCTTGCC. 
We used standard conditions recommended by 
the kit manufacturer (Promega) and separated the 
reactions on a 4% polyacrylamide gel at 4°C and 
160 V. Consensus oligonucleotides for Sp1 and 
EGR1 were purchased from Promega, and the 
following antibodies were used in supershift as-
says: Sp1 (sc-59X), Sp3 (sc-644X), and goat and 
rabbit IgG (Santa Cruz). A chromatin immuno-
precipitation assay was performed with the use 
of a commercially available kit (Upstate), accord-
ing to the manufacturer’s instructions (see the 
Supplementary Appendix).
Statistical Analysis
The genotype and allele frequencies were deter-
mined by direct counting. The genotype frequen-
cies of the groups of patients and control subjects 
(in group 1, in group 2, and in the combined 
group, without consideration of serologic and 
clinical subgroups) were in Hardy–Weinberg equi-
librium. The polymorphism was analyzed as an 
individual biallelic marker at a single locus. We 
used chi-square analysis, the Cochran–Armitage 
chi-square test for trend, and logistic-regression 
models to compare the distribution of the G−945C 
genotype among the groups of patients and con-
trol subjects.
Polytomous (multinomial) logistic-regression 
analyses were performed with the 500 control sub-
jects as the base level and two possible outcomes 
of disease (with or without the specified feature) 
or more than two in the case of the antibodies, 
which were mutually exclusive. Polytomous logis-
tic regression was also used in a case–case analy-
sis to investigate the association between mutu-
ally exclusive serologic groups, with the group 
that was negative for both anti–topoisomerase I 
and anticentromere antibodies used as the con-
trol group. Since clinical features of the disease 
were not necessarily mutually exclusive, we ana-
lyzed their association with the G−945C genotype 
in a case–case approach with the use of logistic-
regression models in which the genotype distri-
bution in patients who presented with each clini-
cal feature was compared with that in patients 
without that feature. Results are expressed as 
odds ratios and 95% confidence intervals. Statis-
tical calculations were performed with the use 
of Stata statistical software (version 9).
The significance of the difference between 
genotype groups in promoter–reporter regions 
and chromatin immunoprecipitation assays was 
estimated by means of a two-tailed Student’s t-test 
(assuming equal variance) with the use of Excel 
(Microsoft).
R esult s
Identification of Sequence Variants
The region of the CTGF promoter in the vicinity of 
position −945 has not been functionally charac-
terized, but sequence inspection and database 
searches16 have indicated that the single-base sub-
stitution at this site could affect DNA binding of 
several transcription factors, including paired box 
gene 3 (Pax3), upstream stimulatory factor (USF), 
myeloid zinc finger (MZF), and Sp1-like factors. 
The high prevalence of this polymorphism in our 
study population that was primarily of European 
descent and a strong likelihood that it binds Sp1-
like factors, which have been implicated in the 
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pathogenesis of systemic sclerosis,22-24 made this 
SNP our prime candidate.
We screened our initial group of patients and 
control subjects for this polymorphism, and a 
significant difference in genotype distribution 
was found between the 200 patients with system-
ic sclerosis and the 188 control subjects (P = 0.03), 
with an excess of the GG genotype in the disease 
group (in 27.5% of the patients vs. 18.0% of the 
control subjects, P = 0.03). The association between 
the GG genotype and the diagnosis of systemic 
sclerosis was subsequently confirmed in an inde-
pendent set (group 2), consisting of 300 patients 
with systemic sclerosis and 312 control subjects 
(difference in genotype distribution, P = 0.001; pro-
portion of G homozygotes, 32.3% in the group 
with systemic sclerosis vs. 19.9% in the control 
group; P<0.001) (Table 2). When the combined 
group of 500 patients with systemic sclerosis was 
compared with the combined group of 500 con-
trol subjects, the difference in the frequency of 
G homozygotes reached strong statistical signifi-
cance (30.4% vs. 19.2%; odds ratio, 2.2; P<0.001 
for trend) (Table 2). The genotype distribution of 
the G−945C polymorphism in all analyzed sub-
groups (group 1 and group 2) is shown in Table 
2 of the Supplementary Appendix.
A significant trend toward an increase in the 
G allele copy number was observed in 155 pa-
tients with anti–topoisomerase I antibodies (odds 
ratio for CG, 1.3; odds ratio for GG, 3.3; P<0.001 
for trend) and in 166 patients with anticentro-
mere antibodies (odds ratio for CG, 1.7; odds 
ratio for GG, 2.7; P<0.001 for trend) but not in 
179 patients with autoantibodies other than anti–
topoisomerase I or anticentromere antibodies 
(odds ratio for CG, 1.1; odds ratio for GG, 1.3; 
P = 0.35 for trend) (Table 2, and Table 4 of the 
Supplementary Appendix).
We further compared the association between 
the G−945C genotype and antibody status in a 
case–case analysis. There was a significant in-
crease in the G allele copy number in samples 
that were positive for anti–topoisomerase I anti-
bodies (P<0.005 by the Cochran–Armitage test) 
and for those that were positive for anticentro-
mere antibodies (P<0.05) as compared with sam-
ples that were negative for both; no significant 
difference was found between samples that were 
positive for anti–topoisomerase I antibodies and 
those that were positive for anticentromere anti-
bodies (P = 0.24 by the Cochran–Armitage test).T
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The association between anti–topoisomerase I 
antibodies and fibrosing alveolitis in systemic 
sclerosis is well established25 and raises the ques-
tion of whether the strong association between 
this polymorphism and anti–topoisomerase I anti-
bodies also reflects an association with fibrosing 
alveolitis. Since clinical phenotypes of the dis-
ease were not necessarily mutually exclusive, we 
performed a logistic-regression analysis to com-
pare the G−945C genotype between patients with 
and those without each clinical feature using a 
case–case approach. This analysis revealed a sig-
nificant association between the G allele and the 
presence of fibrosing alveolitis when compared 
with patients without fibrosing alveolitis (odds 
ratio for CG, 1.3; odds ratio for GG, 1.8; P<0.05). 
Moreover, this association remained significant 
after adjustment for sex and autoantibody group 
(odds ratio for CG, 1.6; odds ratio for GG, 2.0; 
P<0.05).
When the association between the G allele 
copy number and the presence or absence of fi-
brosing alveolitis was analyzed separately in each 
autoantibody group (Fig. 1A), a significant asso-
ciation was observed in the group that was posi-
tive for anti–topoisomerase I antibodies (P<0.05 
by the Cochran–Armitage test), and a nonsignifi-
cant trend was observed in the small group of 
patients who were positive for anticentromere 
antibodies (P = 0.11). However, no trend was found 
in the group without anti–topoisomerase I or 
anticentromere antibodies (P = 0.48).
In a polytomous logistic-regression model 
with healthy control subjects as the base category 
and separate outcomes for patients with differ-
ent autoantibodies and with or without fibrosing 
alveolitis, the combination of anti–topoisomer-
ase I antibodies and fibrosing alveolitis was strong-
ly associated with an increase in the G allele 
copy number (odds ratio for CG, 1.6; odds ratio 
for GG, 4.6; P<0.001). Similar results were ob-
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Figure 1. The G−945C Polymorphism in CTGF as a Risk 
Factor for Fibrosing Alveolitis in Systemic Sclerosis.
Panel A shows the prevalence of fibrosing alveolitis ac-
cording to the −945 genotype in CTGF in patients with 
systemic sclerosis who have either anti–topoisomerase I 
antibodies or anticentromere antibodies or lack both.  
T bars represent the standard error of proportions ob-
tained with the use of generalized linear models. Panel B 
shows CTGF promoter–reporter constructs used in trans-
fection assays, indicating the polymorphic site in rela-
tion to cloning sites and functional sites in the proximal 
promoter.23,26 Panel C shows the relative luciferase 
 expression in human lung fibroblasts transfected with 
reporter constructs containing a promoter sequence 
cloned from 10 unrelated subjects, five G alleles and 
five C alleles. A thymidine kinase promoter–renilla lucif-
erase vector was used as a transfection efficiency con-
trol. Shown are the means (+SE) of pooled data from 
three observations (triplicate cultures) for five constructs 
at basal conditions and after stimulation with 1 U of 
thrombin per milliliter; data are representative of two 
experiments. P<0.001 for the G alleles as compared 
with the C alleles at basal conditions (luciferase activity 
increased by a factor of 3.3) and after thrombin stimu-
lation (increased by a factor of 2.9). SMAD denotes 
similar to mothers against decapentaplegic homo-
logue, BCE-1 basal control element 1, Luc promoter–
luciferase, and RLU relative luciferase units.
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served for anticentromere-positive systemic scle-
rosis either with fibrosing alveolitis (odds ratio 
for CG, 1.6; odds ratio for GG, 2.4; P = 0.002) or 
without fibrosing alveolitis (odds ratio for CG, 
3.6; odds ratio for GG, 10.1; P = 0.01) but not in 
the groups without anti–topoisomerase I or anti-
centromere antibodies, regardless of the presence 
or absence of fibrosis. By contrast, after adjust-
ment for autoantibody group, no significant as-
sociation was found in patients with systemic 
sclerosis between the G allele copy number and 
the presence or absence of diffuse skin involve-
ment, pulmonary hypertension, or renal crisis 
(Tables 3 and 4 of the Supplementary Appendix).
Promoter-Activity Analysis
We investigated whether the polymorphism at po-
sition −945 affects the transcriptional activity of 
the CTGF promoter in primary pulmonary fibro-
blasts. We chose these cells because the lung is 
the most strongly implicated organ in our study, 
and fibroblasts are major producers of CTGF in 
the lung.27 We cloned 1.6-kb DNA fragments 
amplified by PCR spanning the polymorphic site 
from patients with defined CC or GG genotypes 
(five in each group) into a 4.5-kb promoter–
 reporter construct (p-4.5–CTGF–Luc) (Fig. 1B), and 
the genotype was verified by sequencing. Tran-
sient transfection assays with the use of these 
promoter–reporter constructs showed signifi-
cantly higher transcriptional activity for the G al-
lele constructs, both under basal conditions and 
after thrombin stimulation at 1 U per milliliter 
(Fig. 1C). Thrombin stimulation showed that the 
absolute transcriptional activity in the G allele 
was three times that in the C allele under profi-
brotic conditions.
Formation of Protein–DNA Complex
We next assessed the interactions between protein 
and DNA at this site with the use of fibroblast 
nuclear extracts and EMSA. A striking difference 
between the G allele and C allele was observed, 
showing strong binding of nuclear proteins to 
the C allele, with two distinct complexes formed, 
but with a lack of binding to the G allele probe 
(Fig. 2A). Since the C variant forms part of a 
TCCTCCC element (polymorphic base underlined), 
an atypical Sp1-like binding site reported in the 
collagen type Iα1 gene,28 we investigated whether 
the complexes contained such factors. Specificity 
of binding, tested by competition with unlabeled 
oligonucleotides, showed a loss of binding with 
the use of a C allele probe and an Sp1 consensus 
oligonucleotide, but not with the G allele probe 
and a consensus probe for another GC-rich bind-
ing factor, early growth response 1 (EGR1) (Fig. 
2A). The use of specific supershift antibodies 
showed that Sp3 is the major factor binding to 
this site (C allele), with weak binding also of Sp1 
(Fig. 2B).
We performed a chromatin immunoprecipita-
Figure 2 (facing page). Action of Sp3 in the Preferential 
Binding of the C Allele and Repression of Transcription.
In Panel A, electrophoretic mobility shift assay (EMSA) 
with 32P-labeled probes containing the C and G alleles 
at position −945 shows differential transcription-factor 
binding to G−945C. Unlabeled oligonucleotides were 
used as competitors, as indicated, to demonstrate 
specificity of binding. Sp1 and early growth response 1 
(EGR1) are consensus site oligonucleotides. In Panel B, 
EMSA using a labeled C-allele probe together with spe-
cific antibodies and IgG controls (goat [G] and rabbit [R] 
IgG) shows that Sp3 is the major factor binding to the 
C allele at position −945. Panel C shows the results of a 
semiquantitative chromatin immunoprecipitation assay 
using two control fibroblast preparations, a GG and a 
CC genotype, as an example. Input (10%) denotes the 
DNA sample before immunoprecipitation, diluted by a 
factor of 10 and used as a positive control; IP immuno-
precipitation; and Ab antibody. In Panel D, the mean 
(+SE) ratios of Sp1 to Sp3 PCR product, measured by 
densitometry, are shown for pooled data from five in-
dependent experiments. P<0.01 for the GG genotype as 
compared with the CC genotype in control cells (ratio 
increased by a factor of 5.8), and P<0.001 for the GG 
genotype as compared with the CC genotype in cells 
from patients with systemic sclerosis (increased by a 
factor of 3.3). Panel E shows that Sp3 acts as a repres-
sor at −945C. Luciferase expression from a G allele con-
struct, p-4.5–CTGF–Luc (p-4.5G), and the correspond-
ing C allele construct (p-4.5C), derived by site-directed 
mutagenesis from p-4.5–CTGF–Luc, is cotransfected 
with an expression vector for Sp3 (pSp3) or an empty 
expression vector (pEV). Data shown are means (+SE) 
of three independent experiments. The asterisk denotes 
P<0.01 for the difference between the effect of pSp3 
and pEV on p-4.5C under basal conditions (a factor of 
0.65). The dagger denotes P<0.001 for the difference 
between the effect of pSp3 and pEV on p-4.5C after 
thrombin stimulation (a factor of 0.47). Panel F shows 
a proposed model of interaction of the polymorphic 
site with the proximal promoter in the CTGF gene. The 
balance of complex components and transcriptional 
activity — for example, through acetylation (Ac) and 
phosphorylation (P) — is probably affected by the loss 
of Sp3 binding at position −945. Histone deacetylase 
(HDAC) and p300, a histone acetylase, may form parts 
of this complex together with Sp1, Sp3, SMAD protein, 
and other factors.
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tion assay using pulmonary fibroblasts that were 
homozygous for either cytosine or guanine at 
position −945. Chromatin was immunoprecipi-
tated with the use of specific anti-Sp1 and anti-
Sp3 antibodies, and DNA that was extracted from 
five independent experiments was amplified by 
CTGF-promoter–specific PCR spanning the poly-
morphic site. Binding of Sp3 and Sp1 was demon-
strated in both CC and GG homozygote cells 
(Fig. 2C), a finding that might be explained by 
the presence of flanking Sp-factor sites (which 
was confirmed by sequencing). However, there was 
a strong and significant shift in the ratio of Sp1 
binding to Sp3 binding toward higher ratios in 
GG homozygote cells (Fig. 2D). This shift was 
caused by the combination of a moderate loss in 
Sp3 binding and a dramatic gain in Sp1 binding 
(Fig. 2C). The allelic difference was observed in 
cells from both patients with systemic sclerosis 
and control subjects, with cells from patients 
with systemic sclerosis having a generally higher 
ratio of Sp1 to Sp3 binding than cells from con-
trol subjects.
Site-Directed Mutagenesis  
and Sp3 Overexpression
Unlike Sp1, Sp3 has been reported to act as a 
transcriptional repressor or as an activator that is 
weaker than Sp1 but is competing for the same 
site.29 This finding would be consistent with our 
finding that enhanced transcriptional activity of 
the G allele promoter constructs correlated with 
a lack of Sp3 binding to this site. To test this hy-
pothesis further, and to avoid influences by other 
putative sequence variants in the amplified frag-
ments from different subjects, we substituted the 
G at this position with a C in the parent p-4.5–
CTGF–Luc construct by site-directed mutagenesis 
and used these two constructs in cotransfection 
assays with an expression vector for Sp3 or an 
empty vector as the control. As predicted, Sp3 over-
expression resulted in a significant repression of 
the C allele construct but had no repressive effect 
on the G construct (and sometimes had a slightly 
enhancing effect) (Fig. 2E).
Discussion
Our data clearly show an association between the 
G−945C polymorphism in CTGF and systemic scle-
rosis, which renders CTGF a susceptibility gene for 
this complex disease. It appears that this SNP is 
associated with defined subgroups of patients 
within the disease, which may contribute to its 
typical heterogeneity. In particular, there is a strong 
association between G-allele homozygotes and 
the presence of specific antibodies (anti–topoi-
somerase I and anticentromere) associated with 
systemic sclerosis, as well as with patients with 
lung fibrosis, in whom the GG genotype repre-
sents a risk that is also independent of the anti-
body profile. Thus, homozygosity for the G allele 
carries an increased risk of scleroderma and, in 
particular, of positivity for anti–topoisomerase I 
antibodies and an increased risk of interstitial 
lung fibrosis among patients with this disorder. 
The association with anticentromere-antibody 
positivity, which has been linked to vascular com-
plications, including isolated pulmonary arterial 
hypertension,25 may suggest that a second mech-
anism involving CTGF overexpression is playing a 
role here. The effects of CTGF on cell prolifera-
tion or extracellular matrix production, if induced 
within certain vessels, could be plausible explana-
tions for this association.
The genetics of autoimmune diseases in gen-
eral is complex. The fact that major-histocom-
patibility-complex alleles confer a risk of such 
disorders has been known for more than 30 years, 
and more recent genetic studies have under-
scored a large number of novel loci and biologic 
pathways.30 Our study adds to a small number of 
recent studies linking polymorphisms of candi-
date genes more strongly with the presence of 
specific autoantibodies than with systemic scle-
rosis itself. The findings include genetic associa-
tions between tumor necrosis factor α and anti-
centromere antibodies,31 between interleukin-10 
and anti–RNA polymerase and anti–U1-ribonucle-
oprotein autoantibodies,32 between endothelin re-
ceptor A and anti–RNA polymerase autoantibod-
ies,33 and between protein tyrosine phosphatase 
nonreceptor type 22 (PTPN22) and anti–topoi-
somerase I and anticentromere antibodies.34
Although there is a well-recognized associa-
tion between particular autoantibodies and the 
clinical profile in patients with systemic sclero-
sis,25 little is known about the cellular and mo-
lecular mechanisms leading to the production 
of these antinuclear antibodies or how they are 
linked to particular organ involvement.35 How-
ever, some recent reports have suggested mecha-
nisms by which autoantibodies can cause tissue 
damage at a cellular level,36,37 providing the miss-
ing connection between antibody profile and or-
gan involvement. Our study indicates that CTGF, 
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through its biologic effects (e.g., cell survival, 
differentiation, and proliferation38) may be con-
tributing to the pathogenesis of systemic sclero-
sis in a manner specific to either organs or cells. 
In this way, dysregulation of CTGF could direct-
ly contribute to the processes causing organ-spe-
cific damage associated with autoimmunity in 
systemic sclerosis. A possible alternative explana-
tion for the associations we observed is that the 
effect of the CTGF polymorphism does not con-
tribute to disease manifestations unless there is 
underlying tissue damage of a certain type (e.g., 
that associated with the presence of anti–topoi-
somerase I antibodies). Further detailed function-
al genetic studies will be required to address 
these issues. A third possibility is that the SNP 
is in linkage disequilibrium with another func-
tional variant.
We have shown that the presence of a C allele 
at position −945 is critical for transcriptional sup-
pression of the CTGF gene and that such suppres-
sion is mediated through Sp3 binding. This sup-
pression would result in reduced CTGF production 
and potential protection against CTGF overex-
pression in disorders such as systemic sclerosis, 
in which a persistent wound-healing response ap-
pears to be an underlying pathogenic process. 
Such a functional explanation would be in agree-
ment with the observation that the G allele is as-
sociated with systemic sclerosis, in which CTGF 
overexpression is generally observed. Thus, the 
functional experiments we describe not only un-
equivocally demonstrate differences in the tran-
scriptional activity of the C and G alleles and 
differential DNA binding in vitro and in vivo but 
also identify a novel major repressor site in the 
CTGF promoter (the C allele).
Our chromatin immunoprecipitation assays 
showed that fibroblasts from patients with sys-
temic sclerosis had an overall ratio of Sp1 to Sp3 
binding that was higher than that of cells from 
control subjects. On the basis of previous reports 
that Sp1 often acts as a stronger activator than 
Sp3 and that Sp3 also often acts as a repressor 
(depending on the binding site and conditions),39 
the increased shift in the ratio of Sp1 to Sp3 prob-
ably would alter the rate of transcription and 
govern higher activity. This hypothesis is consis-
tent with an overall increase in the transcription-
al activity of CTGF in fibroblasts from patients 
with systemic sclerosis, as we have shown previous-
ly,23 and with enhanced Sp1 binding activity.22,24 
From a genetic point of view, our chromatin im-
munoprecipitation assays showed that the ratios 
of Sp1 to Sp3 binding within each cell type were 
approximately three times as high for GG homo-
zygote cells as for CC homozygotes, a finding 
that was consistent with higher transcriptional 
activity from the G alleles. The ratios of Sp1 to 
Sp3 binding in the fibroblasts from patients with 
systemic sclerosis with a CC genotype fell within 
the higher range in cells from control subjects 
with the GG genotype (Fig. 2C). This finding sug-
gests that the effect of the polymorphism is super-
imposed on an underlying imbalance in the 
Sp1–Sp3 system in lung fibroblasts from patients 
with systemic sclerosis.22 
On the basis of our findings, we propose a 
model in which the absence of a strong Sp3 site 
within the context of the promoter, as in the 
G allele, could change the balance of the basic 
transcription complex toward enhanced transcrip-
tion (e.g., through altered acetylation or phos-
phorylation) (Fig. 2F). From an evolutionary per-
spective, sequence comparison with the CTGF 
orthologues of other species suggests that the 
C allele, the more prevalent allele in humans, 
has evolved recently (see the figure in the Supple-
mentary Appendix). Although this finding re-
quires confirmation through more extensive 
study, it implies that there is strong positive se-
lection and the possibility of advantages for this 
repressor site in humans.
In summary, our study shows the direct genet-
ic association between CTGF and systemic sclero-
sis and identifies a CTGF risk genotype involving 
a polymorphism within a novel Sp3-dependent 
transcriptional repressor site. The G allele is 
strongly linked to transcriptional activation of 
CTGF and to the risk of systemic sclerosis, par-
ticularly in patients with anti–topoisomerase I 
autoantibodies and pulmonary fibrosis. Thus, our 
findings not only identify a novel regulatory 
mechanism governing CTGF promoter activity but 
also directly place CTGF on the genetic map of 
human disease. These data provide new insight 
into the pathogenesis of systemic sclerosis, includ-
ing clues to the mechanisms leading to specific 
disease subtypes. Moreover, they may also be 
relevant to mechanisms underlying a wide range 
of other human disorders with a fibrotic com-
ponent.
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